Rolapitant: A Review in Chemotherapy-Induced Nausea and Vomiting.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

1. Pharmacokinetics, safety, and population pharmacokinetic profiles of RitanineFrontiers in pharmacology · 2026
   Trial
2. Predictive Model of Chemotherapy-Induced Myelosuppression for Patients with Esophageal Cancer.Cancer control : journal of the Moffitt Cancer Center
   Trial
3. Therapeutic potential of spiro compounds againstRSC medicinal chemistry · 2025
   Review
4. Neurokinin-1 receptor antagonists in the current management of chemotherapy-induced nausea and vomiting.Frontiers of medicine · 2025
   Review
5. Identification of an Intravenous Injectable NK1 Receptor Antagonist for Use in Traumatic Brain Injury.International journal of molecular sciences · 2024
   Article
6. Synthetic Routes to Approved Drugs Containing a Spirocycle.Molecules (Basel, Switzerland) · 2023
   Review
7. External Application of Traditional Chinese Medicine in the Prevention and Treatment of Nausea and Vomiting Caused by Chemotherapy of Non-Small-Cell Lung Cancer: A RCT Study.Evidence-based complementary and alternative medicine : eCAM · 2022
   Article
8. Chemotherapy-induced nausea and vomiting control in pediatric patients receiving ifosfamide plus etoposide: a prospective, observational study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
   Observational
9. Pharmacometabolomic prediction of individual differences of gastrointestinal toxicity complicating myelosuppression in rats induced by irinotecan.Acta pharmaceutica Sinica. B · 2019
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as